

สมุนไพรกับภาวะต่อมลูกหมากโต

เอกสารอ้างอิง

1. Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the treatment of non-neurogenic male LUTS: EAU guideline. 2011.
2. Sarma AV and Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 2012; 367:248-57.
3. Bone K. A Clinical Guide to Blending Liquid Herbs. Edinburgh. UK: Churchill Livingstone; 2003:400-404.
4. Gruenwald J, Brendler T, Jaenicke C, et al. (eds.). PDR for herbal medicines (2nd Edition). New Jersey: Medical Economic Company, 2000: 858pp.
5. Allkanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 2015;126:42-56.
6. Marzano R, Dinelli N, Ales V, Bertozzi MA. Effectiveness on urinary symptoms and erectile function of Prostamev Plus® vs only extract *Serenoa repens*. Arch Ital Urol Androl. 2015 Mar 31;87(1):25-7.
7. Magri V, Marras E, Restelli A, Wagenlehner FM, Perletti G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. Exp Ther Med 2015;9(3):658-66.
8. Bertaccini A, Giampaoli M, Cividini R, et al. Observational database *Serenoa repens* (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) project. Arch Ital Urol Androl 2012;84(3):117-22.
9. Giulianelli R, Pecoraro S, Sepe G, et al. Multicentre study on the efficacy and tolerability of an extract of *Serenoa repens* in patients with chronic benign prostate conditions associated with inflammation. Arch Ital Urol Androl 2012;84(2):94-8.
10. Sinescu I, Geavlete P, Multescu R, et al. Long-term efficacy of *Serenoa repens* treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol Int 2011;86(3):284-9.
11. Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA. *Serenoa repens* extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003;92(3):267-70.
12. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998;280(18):1604-9.
13. Ryu YW, Lim SW, Kim JH, Ahn SH, Choi JD. Comparison of tamsulosin plus *Serenoa repens* with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int 2015;94(2):187-93.
14. Argirović A(1), Argirović D(2). Does the addition of *Serenoa repens* to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia? Vojnosanit Pregl 2013;70(12):1091-6.
15. Aliaev luG, Vinarov AZ, Demidko luL, Spivak LG. The results of the 10-year

- study of efficacy and safety of *Serenoa repens* extract in patients at risk of progression of benign prostatic hyperplasia. *Urologiia* 2013;(4):32-6. [Article in Russian]
16. Morgia G, Cimino S, Favilla V, et al. Effects of *Serenoa repens*, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. *Int Braz J Urol* 2013;39(2):214-21.
 17. Minutoli L, Bitto A, Squadrito F, et al. *Serenoa repens*, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia. *Curr Med Chem* 2013;20(10):1306-12.
 18. Andriole GL, McCullum-Hill C, Sandhu GS, Crawford ED, Barry MJ, Cantor A. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial *J Urol*. 2013;189(2):486-92.
 19. Iacono F, Prezioso D, Illiano E, Ruffo A, Romeo G, Amato B. Observational study: daily treatment with a new compound "Tradamixina" plus *Serenoa repens* for two months improved the lower urinary tract symptoms. *BMC Surg* 2012;12 Suppl 1:S22.
 20. Suter A, Saller R, Riedi E, Heinrich M. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. *Phytother Res* 2013;27(2):218-26.
 21. Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. *JAMA*. 2011;306(12):1344-51.
 22. Jibrin I, Erinle A, Saidi A, Aliyu ZY. Saw palmetto-induced pancreatitis. *South Med J* 2006;99(6):611–612.
 23. Wargo KA, Allman E, Ibrahim F. A possible case of saw palmetto-induced pancreatitis. *South Med J* 2010;103(7):683–685.
 24. Lapi F, Gallo E, Giocaliere E, et al. Acute liver damage due to *Serenoa repens*: a case report. *Br J Clin Pharmacol* 2010;69(5):558–560.
 25. Villanueva S, González J. Coagulopathy induced by saw palmetto: a case report. *Bol Asoc Med P R* 2009;101(3):48–50.
 26. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. *J Intern Med* 2001;250(2):167-9.
 27. Capodice JL, Katz AE. What patients take without telling you: holistic approach for BPH. *World J Urol* 2006;24(4):378-82.
 28. วิกีพีเตีย. ปาล์มขวด [Internet]. 2015 [cited 2015 Jun 23]. Available from: <https://th.wikipedia.org/wiki/%E0%B8%9B%E0%B8%B2%E0%B8%A5%E0%B9%8C%E0%B8%A1%E0%B8%82%E0%B8%A7%E0%B8%94>
 29. Pérez Y, Menéndez R, Mas R, Gonzales RM. In vitro effect of D-004, a lipid extract of the fruit of the Cuban royal palm (*Roystonea regia*), on prostate steroid 5 α reductase activity. *Curr Ther Res* 2006;67:396-405.

30. Carbajal D, Molina V, Mas R, Arruzazabala ML, Therapeutic effect of D-004, a lipid extract from *Roystonea regia* fruits, on prostate hyperplasia induced in rats. *Drugs Exp Clin Res* 2005;31(5-6):193-7.
31. Noa M, Arruzazabala ML, Carbajal D, Más R, Molina V. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. *Int J Tissue React* 2005;27(4):203-11.
32. Arruzazabala ML, Más R, Molina V, Noa M, Carbajal D, Mendoza N. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phenylephrine in rats. *Drugs R&D*2006;7(4):233-41.
33. Arruzazabala ML, Molina V, Más R, Carbajal D. Effects of D-004, a lipid extract from the royal palm (*Roystonea regia*) fruits, tamsulosin and their combined use on urodynamic changes induced with phenylephrine in rats. *Arzneimittelforschung* 2008;58(2):81-5.
34. Gutiérrez A, Gámez R, Noa M, et al. Long-term (24 months) carcinogenicity study of D-004, a lipid extract from *Roystonea regia* fruits, in sprague dawley rats. *Int J Toxicol* 2015;34(2):138-50.
35. Gámez R, Mas R, Noa M, et al. Oral acute and subchronic toxicity of D-004, a lipid extract from *Roystonea regia* fruits, in rats. *Drugs Exp Clin Res* 2005;31(3):101-8.
36. Gutiérrez A, Gámez R, Mas R, et al. Oral subchronic toxicity of a lipid extract from *Roystonea regia* fruits, in mice. *Drug Chem Toxicol* 2008; 31(2):217-28.
37. Gutiérrez A, Gámez R, Noa M, et al. One year oral toxicity of D-004, a lipid extract from *Roystonea regia* fruits, in sprague dawley rats. *Food Chem Tox* 2011;49(11):2855-61.
38. Gutiérrez A, Gámez R, Arencibia DF, et al. Assessment the potential genotoxic of D-004, for inducing chromosomal aberrations in bone marrow of mice. *Rev CENIC Cien Biol* 2010;41.
39. Gutiérrez A, Pardo B, Gámez R, et al. Effects of in utero exposure to D-004, a lipid extract from *Roystonea regia* fruits, in the male rat. Comparison with Finasteride. *J Med Food*. 2011;14(12): 1663-9.
40. López E, Molina V, Illnait J, et al. Antioxidant effects of D-004, a lipid extract from the *Roystonea regia* fruit, on the plasma of healthy men. *Asian J Androl* 2009;11(3):385-92.
41. วิวัฒนา จิรัจฉนริยาภูล. มะเขือเทศ. จุลสารข้อมูลสมุนไพร 2543;17(3):3-11.
42. Levy J, Sharoni Y, The functions of tomato lycopene and its role in human health. *HerbalGram* 2004;62:49–56.
43. Campbell JK, Canene-Adams K, Lindshield BL, Boileau TW, Clinton SK, Erdman Jr. JW. Tomato phytochemicals and prostate cancer risk. *J Nutr* 2004;134(12):3486S-3492S.
44. Zhang X, Wang Q, Neil B, Chen X. Effect of lycopene on androgen receptor and prostate-specific antigen velocity. *Chin Med J* 2010;123(16):2231-6.

45. Heber D, Lu QY. Overview of mechanisms of action of lycopene. *Exp Biol Med (Maywood)* 2002;227(10):920-3.
46. La Placa M, Pazzaglia M, Tosti A. Lycopenaemia. *J Eur Acad Dermatol Venereol* 2000;14(4):311-2.
47. Matulka RA, Hood AN, Griffiths JC. Safety evaluation of a natural tomato oleoresin extract derived from food-processing tomatoes. *Regul Toxicol Pharmacol* 2004;39(3):390-402.
48. Chen L, Stacewicz-Sapuntzakis M, Duncan C, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. *J Natl Cancer Inst* 2001;93(24):1872-9.
49. Edinger MS and Koff WJ. Effect of the consumption of tomato paste on plasma prostate-specific antigen levels in patients with benign prostate hyperplasia. *Braz J Med Biol Res* 2006;39(8):1115-9.
50. Schwarz S, Obermüller-Jevic UC, Hellmis E, Koch W, Jacobi G, Biesalski HK. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. *J Nutr* 2008;138(1):49-53.
51. Park E, Stacewicz-Sapuntzakis M, Sharifi R, Wu Z, Freeman VL, Bowen PE. Diet adherence dynamics and physiological responses to a tomato product whole-food intervention in African-American men. *Br J Nutr* 2013;109(12):2219-30.
52. Jung SK, Kim K, Tae K, Kong G, Kim MK. The effect of raw vegetable and fruit intake on thyroid cancer risk among women: a case-control study in South Korea. *Br J Nutr* 2013;109(1):118-28.
53. Mazdak H, Mazdak M, Jamali L, Keshteli AH. Determination of prostate cancer risk factors in Isfahan, Iran: a case-control study. *Med Arh* 2012;66(1):45-8.
54. Salem S, Salahi M, Mohseni M, Ahmadi H, Mehraei A, Jahani Y, Pourmand G. Major dietary factors and prostate cancer risk: a prospective multicenter case-control study. *Nutr Cancer* 2011;63(1):21-7.
55. Tomita LY, Roteli-Martins CM, Villa LL, Franco EL, Cardoso MA; BRINCA Study Team. Associations of dietary dark-green and deep-yellow vegetables and fruits with cervical intraepithelial neoplasia: modification by smoking. *Br J Nutr* 2011;105(6):928-37.
56. Liu AG, Volker SE, Jeffery EH, Erdman JW Jr. Feeding tomato and broccoli powders enriched with bioactives improves bioactivity markers in rats. *J Agric Food Chem* 2009;26;57(16):7304-10.
57. วิมล ศรีศุข. กินมะเขือเทศอย่างไรได้ประโยชน์ (lycopene) สูง. *มหิตลสาร* 2558;40(1):24.
58. วิมล ศรีศุข. Gac ผลไม้สีแดงของเวียดนาม. *จุลสารข้อมูลสมุนไพร* 2551;25(2):3-9.
59. PDR for Herbal Medicines. third ed. Thomson PDR at Montvale. USA 2004.
60. Badr SE, Shaaban M, Elkholy YM, et al. Chemical composition and biological activity of ripe pumpkin fruits (*Cucurbita pepo* L.) cultivated in Egyptian habitats. *Nat Prod Res* 2010;1-16.
61. Tsai YS, Tong YC, Cheng JT, Lee CH, Yang FS, Lee HY. Pumpkin seed oil and phytosterol-F can block testosterone

- /prazosin-induced prostate growth in rats. *Urol Int* 2006;77(3):269-74.
62. Gossell-Williams M, Davis A, O'Connor N. Inhibition of testosterone-induced hyperplasia of the prostate of Sprague–Dawley rats by pumpkin seed oil. *J Med Food* 2006;9(2):284-6.
 63. Steenkamp V. Phytomedicines for the prostate. *Fitoterapia* 2003;74(6):545-52.
 64. Capasso C, Gaginella TS, Grandolini G, Izzo AA. *Phytotherapy - A Quick Reference to Herbal Medicine*, Springer-Verlag, Berlin Heidelberg, 2003.
 65. Schiebel-Schlosser G, Friederich M. Phytotherapy of BPH with pumpkin seeds-a multicenter clinical trial. *Z Phytother* 1998;19:71-6.
 66. Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. *Nutr Res Pract* 2009;3(4):323-7.
 67. Dvorkin L, Song KY. Herbs for benign prostatic hyperplasia. *Ann Farmacother* 2002;36:1443-52.
 68. Buck AC. Phytotherapy for the prostate. *Br J Urol* 1996;78(3):325-36. (MR121)
 69. Kimura M, Kimura I, Nakase K, Sonobe T, Mori E. Micturition activity of pollen extract: contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig. *Planta Med* 1986;2:148-51.
 70. Wikstrom P, Bylund A, Zhang JX, Hallmans G, Stattin P, Bergh A. Rye bran diet increases epithelial cell apoptosis and decreases epithelial cell volume in TRAMP (transgenic adenocarcinoma of the mouse prostate) tumors. *Nutr Cancer* 2005;53(1):111-6.
 71. MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. *BJU Int* 2000;85(7):836-41.
 72. Xu J, Qian WQ, Song JD. A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia. *Zhonghua Nan Ke Xue* 2008;14(6):533-7.
 73. Nahata A, Dixit VK. Ameliorative effects of stinging nettle (*Urtica dioica*) on testosterone-induced prostatic hyperplasia in rats. *Andrologia* 2012;44(1):396-409.
 74. Safarinejad MR. *Urtica dioica* for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. *J Herb Pharmacother* 2005;5(4):1-11.
 75. Lopatkin N, Sivkov A, Schläfke S, Funk P, Medvedev A, Engelmann U. Efficacy and safety of a combination of Sabal and *Urtica* extract in lower urinary tract symptoms-long-term follow-up of a placebo-controlled, double-blind, multicenter trial. *Int Urol Nephrol* 2007;39(4):1137-46.
 76. Engelmann U, Walther C, Bondarenko B, Funk P, Schläfke S. Efficacy and safety of a combination of Sabal and *Urtica* extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. *Arzneimittelforschung* 2006;56(3):222-9.
 77. Sökeland J. Combined Sabal and *Urtica* extract compared with finasteride in men with benign prostatic hyperplasia:

analysis of prostate volume and
therapeutic outcome. BJU Int
2000;86(4):439-42.